14 G/T Au Within 47m of Gold-Bearing Skarn from 26m Depth in 300m Step-Out at Birch Cu-Au Project GlobeNewswire December 08, 2025 VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) — Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) (“Yukon Metals” or the “Company“) is pleased to announce results from the last two holes […]

Gaming and Leisure Properties Expands Board of Directors With Appointment of Michael Borofsky GlobeNewswire December 08, 2025 WYOMISSING, Pa., Dec. 08, 2025 (GLOBE NEWSWIRE) — Gaming and Leisure Properties, Inc. (NASDAQ: GLPI) (the “Company”), announced today that Michael Borofsky has been appointed to the Board of Directors as a new independent director, effective immediately, subject

eToro Group Reports Selected November Business Metrics GlobeNewswire December 08, 2025 NEW YORK, Dec. 08, 2025 (GLOBE NEWSWIRE) — eToro Group Ltd. (“eToro”, or the “Company”) (NASDAQ: ETOR), the trading and investing platform, is reporting the below selected monthly business metrics for November 2025. Assets under Administration (AUA) were $18.8B, up 9% year-over-year. Funded accounts

Cardiff Oncology to Present at Sidoti's Year-End Virtual Investor Conference GlobeNewswire December 08, 2025 SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at

Montara Therapeutics Announces Development Candidate for First BrainOnly(TM)-Enabled Program in TSC-Related Epilepsy and Appoints Chief Business Officer GlobeNewswire December 08, 2025 Montara's BrainOnly platform is designed to prevent peripheral side effects and concentrate neurological drugs' activity in the brain via two-drug combination therapies, comprising its non-brain-penetrant “universal” peripheral blocker development candidate, MT1110, and a brain-penetrant

Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis GlobeNewswire December 08, 2025 KT-621 achieved deep STAT6 degradation across both the 100 mg and 200 mg dose groups tested, with median reductions of 94% and 98% in skin

Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting GlobeNewswire December 08, 2025 Joint presentation by Orchestra BioMed and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization of AVIM Therapy for treatment of uncontrolled hypertension in patients indicated for a pacemaker NEW HOPE, Pa., Dec. 08, 2025 (GLOBE

PyroGenesis Confirms Half-Tonne Order for Immediate Delivery of Titanium Metal Powder Represents first contract under Approved Supplier Status with Global Aerospace Leader GlobeNewswire December 08, 2025 MONTREAL, Dec. 08, 2025 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), the leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology

Mercury Showcases Expanding Portfolio of Electronic Warfare Capabilities at AOC 2025 GlobeNewswire December 08, 2025 ANDOVER, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) — Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a global technology company that delivers mission-critical processing to the edge, will participate in this week's Association of Old Crows (AOC) International Symposium and Convention, showcasing

Gogo makes a strategic investment in Farcast to support new cutting-edge user terminal technology to enhance inflight connectivity for business, military, and government aviation GlobeNewswire December 08, 2025 SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Farcast, a San Francisco-based startup building advanced satellite user terminals, announces that it has received strategic equity investment from